About: Rufinamide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rufinamide Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B49B7-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49B2-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49B3-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49B4-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49B5-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49B6-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Arroyo S: Rufinamide. Neurotherapeutics. 2007 Jan;4(1):155-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17199032 # Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW: Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother. 2007 Aug;8(12):1931-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17696794 # Rufinamide: CGP 33101, E 2080, RUF 331, Xilep. Drugs R D. 2005;6(4):249-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15991887 # Wier HA, Cerna A, So TY: Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. Paediatr Drugs. 2011 Apr 1;13(2):97-106. doi: 10.2165/11586920-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21351809 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours. (en)
http://linked.open...ugbank/indication	Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome. (en)
sameAs	Rufinamide
Title	Rufinamide (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/chemspider/114471 http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/drugbank/DB06201 http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/kegg-drug/D05775 http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/national-drug-code-directory/62856-582-52 http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/pubchem-compound/129228 http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/pubchem-substance/12014051 http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/wikipedia/Rufinamide
http://linked.open...mechanismOfAction	Rufinamide is a triazole derivative antiepileptic that prolongs the inactive state of voltage gated sodium channels thus stabilizing membranes, ultimately blocking the spread of partial seizure activity. (en)
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/6740669
http://linked.open...outeOfElimination	Renally (91%; 66% as CGP 47292, 2% as unchanged drug) and fecally (9%) eliminated. (en)
http://linked.open.../drugbank/synonym	Banzel (en) RUF 331 (en) Xilep (en)
http://linked.open...drugbank/toxicity	The most commonly observed adverse reactions (≥10% and greater than placebo) were headache, dizziness, fatigue, somnolence, and nausea. (en)
http://linked.open...umeOfDistribution	Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day. Volume of distribution is similar between adults and children and is non-linear. (en)
http://linked.open...k/foodInteraction	Food increases plasma concentrations of rufinamide and slightly decreases half-life (by 3%) (en)
http://linked.open...nk/proteinBinding	26.3% - 34.8% with 90% binding to albumin (27%). (en)
http://linked.open...ynthesisReference	Emanuele ATTOLINO, Lino COLOMBO, Ilaria MORMINO, Pietro ALLEGRINI, "METHOD FOR THE PREPARATION OF RUFINAMIDE." U.S. Patent US20100234616, issued September 16, 2010. (en)
foaf:page	http://www.drugs.com/cdi/rufinamide.html http://www.rxlist.com/banzel-drug.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B49BC-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B49C2-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B49C1-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B49BE-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B49BF-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B49C0-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B49D2-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B49BA-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B49D3-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B49B8-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B49BB-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B49B9-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Rufinamide
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B49C8-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B49C9-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B49C3-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B49C4-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B49C6-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B49C5-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B49C7-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions. Bioavailability= 70%-85% (decreases with increasing doses); Tmax, fed and fasted states= 4-6 hours; Cmax, 10 mg/kg/day= 4.01 µL/mL; Cmax, 30mg/kg/day= 8.68 µL/mL; AUC (0h-12h), 10mg/kg/day= 37.8±47 µg·h/mL; AUC (0h-12h), 30mg/kg/day= 89.3±59 µg·h/mL. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	106308-44-5 (en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B49CE-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B49D0-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B49D1-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B49CD-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B49CC-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B49CF-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B49BD-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B49CA-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B49CB-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software